医学
嵌合抗原受体
髓系白血病
免疫疗法
白血病
急性白血病
免疫学
Blinatumoab公司
免疫系统
癌症研究
淋巴细胞白血病
作者
Nicolas Boissel,Florence Rabian
出处
期刊:Therapie
[Elsevier]
日期:2022-03-01
卷期号:77 (2): 241-250
被引量:3
标识
DOI:10.1016/j.therap.2021.12.003
摘要
In the past decade, immunotherapy has emerged as one of the most promising field of therapeutic progress in acute leukemia. Antibody-drug conjugates are now combined to standard chemotherapy backbones in both acute myeloid (AML) and lymphoblastic leukemia (ALL). CD19 targeting immune cell engagers and chimeric antigen receptor (CAR) T-cells have been approved in relapsed/refractory B-cell acute lymphoblastic leukemia and pave the way to promising developments in acute myeloid leukemia. Next generation immune checkpoint inhibitors targeting TIM-3 or CD47 binding by SIRPα on macrophages are tested in combination to hypomethylating agents to improve survival of unfit AML patients with acceptable safety profiles. This review summarizes the antibody-derived strategies developed in the field of acute leukemias with a specific focus on recently approved drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI